Imatinib Induced Facial Skin Hyperpigmentation in a Case of Chronic Myelogenous Leukemia.
| Author | N Valizadeh | en |
| Issued Date | 2011-07-01 | en |
| Abstract | Background:: Imatinib is a tyrosine kinase inhibitor (TKI) which targets BCR-ABL protein in patients with chronic myelogenous leukemia (CML) and c-kit in patients with gastrointestinal stromal tu-mors (GISTs). Skin hypopigmentation is reported during Imatinib therapy. We present a case of CML who developed skin hyperpigmentation in the face during treatment with Imatinib which found chloasma-like appearance. | en |
| DOI | https://doi.org/ | en |
| Keyword | Imatinib | en |
| Keyword | Skin | en |
| Keyword | Hyperpigmentation | en |
| Keyword | Chloasma | en |
| Publisher | Brieflands | en |
| Title | Imatinib Induced Facial Skin Hyperpigmentation in a Case of Chronic Myelogenous Leukemia. | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 73107-pdf.pdf
- Size:
- 133.06 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF